"20"^^ . . "http://www.prolekare.cz/transfuze-hematologie-dnes-clanek/prvni-zkusenosti-ceske-mds-skupiny-s-terapii-5-azacytidinem-u-nemocnych-s-myelodysplastickym-syndromem-s-vyssim-ri-46896" . "Vondr\u00E1kov\u00E1, J." . . "Nov\u00E1kov\u00E1, Ludmila" . "Walterov\u00E1, L." . "Seifertov\u00E1, N." . "1213-5763" . . . "Ulrychov\u00E1, J." . . "Azacytidine; myelodysplastic syndrome; Overall survival; prognostic factors; therapy"@en . "2"^^ . "Ka\u010Dm\u00E1\u0159ov\u00E1, K." . "RIV/00023736:_____/13:00010890" . . "Libiger, J." . "\u010Cerm\u00E1k, Jaroslav" . "Na\u0161e pr\u00E1ce je v\u011Bnov\u00E1na zku\u0161enostem \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem (d\u00E1le jen azacitidin) u nemocn\u00FDch s vy\u0161\u0161\u00EDm rizikem MDS (IPSS st\u0159edn\u00ED II a vysok\u00E9 riziko), s AML do 30 % myeloblast\u016F (MB) ve d\u0159eni \u2028a s chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II (CMML)." . . "Roho\u0148, P." . . . "Prvn\u00ED zku\u0161enosti \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem u nemocn\u00FDch s myelodysplastick\u00FDm syndromem s vy\u0161\u0161\u00EDm rizikem (IPSS st\u0159edn\u00ED 2 a vysok\u00E9 riziko), akutn\u00ED myeloidn\u00ED leukemi\u00ED do 30 % myeloblast\u016F a chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II" . . "Hochov\u00E1, I." . "Na\u0161e pr\u00E1ce je v\u011Bnov\u00E1na zku\u0161enostem \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem (d\u00E1le jen azacitidin) u nemocn\u00FDch s vy\u0161\u0161\u00EDm rizikem MDS (IPSS st\u0159edn\u00ED II a vysok\u00E9 riziko), s AML do 30 % myeloblast\u016F (MB) ve d\u0159eni \u2028a s chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II (CMML)."@cs . "Vozobulov\u00E1, V." . . . "9"^^ . "\u010Cerv\u00EDnek, L." . "Transfuze a hematologie dnes" . "19" . "Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II"@en . "3" . "RIV/00023736:_____/13:00010890!RIV14-MZ0-00023736" . "Prvn\u00ED zku\u0161enosti \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem u nemocn\u00FDch s myelodysplastick\u00FDm syndromem s vy\u0161\u0161\u00EDm rizikem (IPSS st\u0159edn\u00ED 2 a vysok\u00E9 riziko), akutn\u00ED myeloidn\u00ED leukemi\u00ED do 30 % myeloblast\u016F a chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II"@cs . "Our results correlate very well with other published data (AZA 001, CALGB 9221). OS data are comparable with other %22real life%22 studies. It is also important to take into consideration that our group also included very high risk patients (relapsed, refractory to previous treatment, post-transplant patients and AML with more than 30% myeloblasts). Nevertheless, our results are very promising and support the positive effect of azacitidine compared to standard therapy in high risk MDS patients. The analysis performed so far shows that from the aspect of OS, best response correlates with: cytogenetic aberration, peripheral blast count, neutrophil count and ECOG PS."@en . "I, V" . "CZ - \u010Cesk\u00E1 republika" . . "B\u011Blohl\u00E1vkov\u00E1, P." . "\u010Cern\u00E1, O." . "Obernauerov\u00E1, J." . "Pol\u00E1\u010Dkov\u00E1, H." . . . . "Prvn\u00ED zku\u0161enosti \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem u nemocn\u00FDch s myelodysplastick\u00FDm syndromem s vy\u0161\u0161\u00EDm rizikem (IPSS st\u0159edn\u00ED 2 a vysok\u00E9 riziko), akutn\u00ED myeloidn\u00ED leukemi\u00ED do 30 % myeloblast\u016F a chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II" . . "100838" . "S\u00FDkora, M." . "Mu\u017E\u00EDk, J." . "Sch\u00FCtzov\u00E1, M." . . "Prvn\u00ED zku\u0161enosti \u010Cesk\u00E9 MDS skupiny s terapi\u00ED 5-azacytidinem u nemocn\u00FDch s myelodysplastick\u00FDm syndromem s vy\u0161\u0161\u00EDm rizikem (IPSS st\u0159edn\u00ED 2 a vysok\u00E9 riziko), akutn\u00ED myeloidn\u00ED leukemi\u00ED do 30 % myeloblast\u016F a chronickou myelomonocyt\u00E1rn\u00ED leukemi\u00ED II"@cs . . "[47DB57A47058]" . "Initial experience of Czech MDS Group with 5-azacytidine in patients with high risk myelodysplastic syndromes (IPSS intermediate II and high), acute myeloid leukaemia with less than 30% myeloblasts and chronic myelomonocytic leukaemia II"@en . "Jon\u00E1\u0161ov\u00E1, A." .